Veeva Systems Inc. (VEEV)
| Market Cap | 40.09B -15.7% |
| Revenue (ttm) | 3.32B +16.2% |
| Net Income | 941.65M +20.6% |
| EPS | 5.64 +19.7% |
| Shares Out | 162.44M |
| PE Ratio | 43.76 |
| Forward PE | 26.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,620,396 |
| Open | 244.27 |
| Previous Close | 248.46 |
| Day's Range | 242.53 - 247.85 |
| 52-Week Range | 148.05 - 310.50 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 255.93 (+3.71%) |
| Earnings Date | Aug 26, 2026 |
About VEEV
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides ... [Read more]
Financial Performance
In fiscal year 2026, Veeva Systems's revenue was $3.20 billion, an increase of 16.34% compared to the previous year's $2.75 billion. Earnings were $908.91 million, an increase of 27.27%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for VEEV stock is "Buy." The 12-month stock price target is $255.93, which is an increase of 3.71% from the latest price.
News
Veeva Vault CRM Selected by Biogen
Unified commercial platform to help speed the delivery of medicines to patients PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has committed t...
Veeva Vault CRM Selected by Regeneron
Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Regen...
Veeva assumed with an Overweight at Piper Sandler
Piper Sandler analyst Billy Fitzsimmons assumed coverage of Veeva (VEEV) with an Overweight rating with a price target of $295, up from $235. The firm says Veeva is a high-quality…
Veeva price target raised to $276 from $232 at Guggenheim
Guggenheim raised the firm’s price target on Veeva (VEEV) to $276 from $232 and keeps a Buy rating on the shares. Veeva appears positioned to at least meet Q2 estimates…
Veeva price target raised to $275 from $235 at Barclays
Barclays raised the firm’s price target on Veeva (VEEV) to $275 from $235 and keeps an Overweight rating on the shares ahead of the earnings report on August 26. The…
Veeva price target raised to $300 from $225 at Oppenheimer
Oppenheimer analyst Ken Wong raised the firm’s price target on Veeva (VEEV) to $300 from $225 and keeps an Outperform rating on the shares. Software sentiment appears to be improving…
Veeva price target raised to $275 from $230 at Stifel
Stifel analyst David Grossman raised the firm’s price target on Veeva (VEEV) to $275 from $230 and keeps a Buy rating on the shares. Veeva is expected to modestly beat…
Veeva says Eli Lilly has committed to Veeva Vault CRM globally
Veeva Systems (VEEV) announced that Eli Lilly and Company (LLY) has committed to Veeva Vault CRM globally. Vault CRM is part of the Vault CRM Suite of applications that provides…
Veeva Vault CRM Selected by Eli Lilly and Company
PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.
Veeva to Release Fiscal 2027 Second Quarter Results on August 26, 2026
PLEASANTON, Calif., Aug. 5, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its second quarter ending July 31, 2026 after market close on August 26, 2026.
Veeva initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Veeva (VEEV) with a Buy rating and $232 price target Veeva remains well positioned for long-term growth, supported by its entrenched role in life sciences software,…
Veeva initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Veeva (VEEV) with a Buy rating and $232 price target
Veeva Introduces New EHS Application for Proactive Risk Management and Intelligent Automation
Environmental, health, and safety solution is part of Veeva Quality Cloud and will deliver real-time insights and streamlined workflows PLEASANTON, Calif., June 25, 2026 /PRNewswire/ -- Veeva Systems ...
Veeva price target lowered to $272 from $296 at JPMorgan
JPMorgan analyst Alexei Gogolev lowered the firm’s price target on Veeva (VEEV) to $272 from $296 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
Veeva acquires Copli, launches Veeva Falcon MLR to accelerate content review
Veeva (VEEV) has acquired Copli, a company dealing in agentic medical, legal, and regulatory solutions for the life sciences industry. Copli is now available as Veeva Falcon MLR, an agentic…
Veeva Acquires Copli, Launches Veeva Falcon MLR to Accelerate Content Review
Now Available, Veeva Falcon MLR Delivers Agentic MLR TM to Significantly Reduce Manual Effort and Shorten Review Cycles PLEASANTON, Calif. and COPENHAGEN, Denmark, June 23, 2026 /PRNewswire/ -- Veeva...
Veeva Systems Transcript: AGM 2026
The meeting covered director elections and auditor ratification, with no additional proposals or shareholder questions. Voting was conducted online, and results will be filed publicly on Form 8-K.
UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite
End-to-end safety foundation to speed case processing and enable automation PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that UCB is unifying its global ...
Veeva price target lowered to $270 from $295 at Mizuho
Mizuho analyst Steven Valiquette lowered the firm’s price target on Veeva (VEEV) to $270 from $295 and keeps an Outperform rating on the shares. The firm updated the company’s model…
Morgan Stanley has ‘constructive bias’ on Veeva at current levels
Morgan Stanley maintains an Equal Weight rating and $215 price target on Veeva (VEEV) shares, but says it has “a constructive bias at these levels” following what the firm calls…
Veeva price target lowered to $235 from $300 at TD Cowen
TD Cowen lowered the firm’s price target on Veeva (VEEV) to $235 from $300 and keeps a Buy rating on the shares. The fiscal Q1 revenue beat and raise suggests…
Veeva Systems Earnings Call Transcript: Q1 2027
Revenue and operating income exceeded guidance, driven by strong execution in AI, CRM, and Crossix. Ostro acquisition and Falcon AI platform signal continued innovation, while guidance remains conservative amid early-stage scaling of key R&D products.
Veeva Systems Earnings release: Q1 2027
Veeva Systems released its Q1 2027 earnings on June 3, 2026, summarizing the period's financial results.
Veeva Systems Slides: Q1 2027
Veeva Systems has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on June 3, 2026.
Veeva Systems Quarterly report: Q1 2027
Veeva Systems has published its Q1 2027 quarterly earnings report on June 3, 2026.